<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866995</url>
  </required_header>
  <id_info>
    <org_study_id>MHCL-01-15052013</org_study_id>
    <nct_id>NCT01866995</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Phytotherapy &quot;Raylis&quot; In Congestive Processes Of The Pelvic Organs (Prostatostasis)</brief_title>
  <official_title>Phase 3 Study of Phytotherapy &quot;Raylis&quot; In Congestive Processes Of The Pelvic Organs (Prostatostasis)Caused By Decrease Of Sexual Activity In Men.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Clinic of Men's Health and Couple Longevity, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Clinic of Men's Health and Couple Longevity, Russia</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of Phytotherapy &quot;Raylis&quot; (Ginseng
      Root Powder 50 mg, False Ginseng Root Powder 50 mg, Codonopsis Root Powder 50 mg, Astragalus
      Membranaceus Root Powder 50 mg, Epimedium Alpinum Herbal Extract 100 mg) In Congestive
      Processes Of The Pelvic Organs (Prostatostasis) In Congestive Processes Of The Pelvic Organs
      (Prostatostasis)
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TRUS prostate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uroflowmetry</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>IPSS</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Congestive Processes Of The Pelvic Organs (Prostatostasis)</condition>
  <condition>Erectile Dysfunction</condition>
  <condition>Sexual Function</condition>
  <arm_group>
    <arm_group_label>Raylis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm (10 men with symptoms of prostatostasis) will get &quot;Raylis&quot; (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard prostatostasis therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raylis plus standard prostatostasis therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm (20 men with symptoms of prostatostasis) will get &quot;Raylis&quot; (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Raylis&quot;</intervention_name>
    <description>&quot;Raylis&quot; (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)</description>
    <arm_group_label>Raylis</arm_group_label>
    <arm_group_label>Raylis plus standard prostatostasis therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard prostatostasis therapy</intervention_name>
    <arm_group_label>standard prostatostasis therapy</arm_group_label>
    <arm_group_label>Raylis plus standard prostatostasis therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-60 years

          -  Symptoms of prostatostasis lasting for at least 3 months during the past 6 months:

          -  Pathological changes on uroflowmetry (maximum flow rate of less than 15 ml / s,
             average urinary flow rate of less than 12 ml / sec)

          -  TRUS Prostate volume more than 22 ml at TRUS

          -  TRUS picture of Prostatostasis

          -  I-PSS 7-20

          -  IIEF-5) - 12-21

        Exclusion Criteria:

          -  Contraindications and limitations to use of the drug Raylis listed in the instructions
             for medical use *

          -  Diabetes mellitus (type 1 and type 2, decompensation)

          -  Neurogenic disorders (acute cerebral circulatory disorders, Alzheimer's disease,
             spinal cord injury)

          -  A history of pelvic trauma

          -  Patients who had undergone radical prostatectomy and other surgical interventions on
             the pelvic organs

          -  Concomitant use of supplements to improve the erectile function, use of the
             anti-androgens, anti-depressants, finasteride.

          -  Diagnosed BPH

          -  Current participation in a clinical trial and / or study medication for 30 days prior
             to inclusion

          -  Any form of substance abuse, mental disorder or condition which, in the opinion of the
             investigator, may complicate communication with the researcher.

          -  The inability or unwillingness to comply with the scheme of visits according to
             protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svetlana Kalinchenko, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic of Men's Health and Couple Longevity, str Zoologicheskaya, 2-7 Moscow Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuliya Tishova, MD PhD</last_name>
    <phone>+79032213276</phone>
    <email>yulya_tishova@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinic Of Men's Health and Couple Longevity</name>
      <address>
        <city>Moscow</city>
        <zip>123242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliya Tishova, MD PhD</last_name>
      <phone>+79032213276</phone>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2013</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ginseng</keyword>
  <keyword>Prostatostasis</keyword>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

